Product Description
radiofrequency ablation (using the Closurefast device) has been shown to cause less pain and require less analgesic intake than laser treatment for vericose veins (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04720027)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Colombia
Approved Indications: None
Known Adverse Events: None
Company: Medtronic
Company Location: DUBLIN L2 2
Company CEO: Geoffrey S. Martha
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Varicose Veins
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| HKUSZH201901013 | N/A |
Unknown status |
Varicose Veins |
2022-06-30 |
|
| ACOART RF CLOSURE | N/A |
Completed |
Varicose Veins |
2022-01-01 |
|
| Five Years | N/A |
Completed |
Other |
2019-01-01 |
|
| 3-RF Study | N/A |
Completed |
Varicose Veins |
2017-03-28 |